UB researchers show first evidence of pharmacogenomic differences in patients' responses to MS drug

BUFFALO, N.Y. - University at Buffalo researchers using the latest computer-assisted technologies of genetic analysis have shown for the first time how a widely used drug for treating multiple sclerosis -- interferon beta (IFN-beta-1a) -- can modulate the expression of particular genes in patients being treated for the disease.

Their results show that IFN-beta-1a initiates different patterns of genetic expression in different MS patients, information that could lead to better, and potentially individualized, treatments.

Results of the study were presented Oct. 21 at the annual meeting of the American Neurological Association in San Francisco by Bianca Weinstock-Guttman, M.D., UB assistant professor of neurology and director of the Baird MS Center at The Jacobs Neurological Institute, the research arm of the UB Department of Neurology. The study also appeared in the September issue of The Journal of Immunology.

The work links gene microarray techniques with the science of pharmacogenomics and pharmacodynamics. Microarrays are tools for measuring the expression of large numbers of genes. Pharmacodynamics uses mathematical models to capture the details of how drugs affect the body's systems over time, starting with the moment of exposure to the drug.

Together, these techniques can be used to find how genes interact with each other and how a cell's regulatory networks control vast batteries of genes simultaneously. Murali Ramanathan, Ph.D., UB associate professor of pharmaceutical sciences, who performed the experimental assays, has broad experience in processing and analyzing this complex information.

"In a small group of patients, we found that the mRNA gene expression in response to IFN-beta-1a increased rapidly in some MS patients, and was low and late in other patients," said Weinstock-Guttman. "We were very surprised that some of the gene markers showed up as early as two hours after we administered the drug. Prior to this work, oth

Contact: Lois Baker
716-645-5000 x1417
University at Buffalo

Page: 1 2 3

Related biology news :

1. Belgian researchers explore revolutionary approach to angiogenesis
2. Award winning researchers reveal potential new role for Glivec
3. $7.5 Million grant to Yale researchers for role of viruses in cancer
4. New anti-inflammatory strategy for cancer therapy identified by UCSD researchers
5. Joslin researchers clarify mechanisms for beta-cell formation
6. Virginia Tech researchers to release findings on Smith River Project
7. Molecular motor myosin VI moves hand over hand, researchers say
8. ASU researchers demonstrate new technique that improves the power of atomic force micrscopy
9. Emory researchers map structure of anti-cancer molecule
10. Leukemia stem cells identified by Stanford researchers
11. EURYI Award given for the first time to 25 young European researchers

Post Your Comments:

(Date:8/21/2019)... WAXHAW, N.C. (PRWEB) , ... August 20, 2019 ... ... the organic development and commercialization of bioactive technologies for the spine, today announced ... The EVOL-SI features a unique surface modification that is proven to improve osseointegration ...
(Date:8/15/2019)... ... August 15, 2019 , ... ... relieve lab staff of routine tasks. That was the message at the world's ... researcher Kalorama Information. The American Association for Clinical Chemistry (AACC) Annual Scientific Meeting ...
(Date:8/14/2019)... ... August 14, 2019 , ... Gateway Genomics , a ... announces inclusion in the 38th annual Inc. 500|5000 list of fastest growing ... qualify, companies must have been founded and generating revenue by March 31, 2015. Ranking ...
Breaking Biology News(10 mins):
(Date:6/11/2019)... ... June 11, 2019 , ... A study released today ... (MSC-EV) are able to incorporate into human CD34+ cells, modifying their gene expression ... also increased the cells’ ability to lodge into bone marrow. This research performed ...
(Date:5/31/2019)... ... 29, 2019 , ... For many years, the primary forms of cancer treatment ... therapies. Advances in immuno-oncology have led to the advent of Chimeric Antigen Receptor T ... cell receptors known as “CARs”. The CAR enables the final product to produce chemicals ...
(Date:5/31/2019)... ... 2019 , ... World Compliance Seminars today announced a live ... Boston, MA. This peer recommended interactive workshop is always selected by professionals at ... off with a compendial treatment of Data Integrity fundamentals. After laying the groundwork, ...
(Date:5/31/2019)... ... May 30, 2019 , ... ... demonstrate an efficient delivery system for the sustained release of human placental stem ... gel system was able to deliver CM into the injured kidney, where it ...
Breaking Biology Technology:
Cached News: